Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Arcturus Therapeutics (Nasdaq: ARCT), a commercial messenger RNA medicines company specializing in infectious disease vaccines and liver and respiratory rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Joseph Payne, President & CEO, will deliver a presentation at the conference in San Francisco on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time. Investors and interested parties can access the presentation webcast and replay through the company's investor relations website at ir.arcturusrx.com/investor-calendar.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time.

A webcast and replay of the presentation will be available on the Investor Relations/Events section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar.

About Arcturus

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241216064393/en/

Arcturus Therapeutics

Public Relations & Investor Relations

Neda Safarzadeh

VP, Head of IR/PR/Marketing

(858) 900-2682

IR@ArcturusRx.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

When is Arcturus Therapeutics (ARCT) presenting at the JP Morgan Healthcare Conference 2025?

Arcturus Therapeutics will present on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

How can investors watch Arcturus Therapeutics' (ARCT) JP Morgan Healthcare Conference presentation?

Investors can watch the presentation webcast and replay through Arcturus' Investor Relations website at ir.arcturusrx.com/investor-calendar.

What is Arcturus Therapeutics' (ARCT) current business focus?

Arcturus Therapeutics is a commercial messenger RNA medicines company focused on developing infectious disease vaccines and treatments for liver and respiratory rare diseases.

Who will represent Arcturus Therapeutics (ARCT) at the 2025 JP Morgan Healthcare Conference?

Joseph Payne, President & Chief Executive Officer of Arcturus Therapeutics, will represent the company at the conference.